1 citations
,
September 2024 in “Dermatological Reviews” Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.
December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)” QLT0267 stops hair follicle cell growth and movement.
April 2016 in “Journal of Investigative Dermatology” A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
October 2023 in “IP Indian Journal of Clinical and Experimental Dermatology” The luliconazole shampoo effectively reduces symptoms of seborrheic dermatitis and is well-tolerated.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
January 2026 in “JPRAS Open” PDLLA scalp injections improved hair regrowth in most patients with non-scarring alopecia.
Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.
59 citations
,
October 2012 in “Pharmaceutical Research” Squalene-based carriers improve delivery of a treatment to hair follicles for alopecia areata.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
19 citations
,
January 2019 in “JAAD case reports” A medication for skin rash also unexpectedly treated hair loss in a patient.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” QMSI is a valuable method for studying drug penetration in skin tissues.
September 2025 in “Cureus” GLP-1 agonists may help treat certain skin conditions.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
September 2017 in “Journal of Investigative Dermatology” RCS-01 is safe and may help rejuvenate aging skin.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
1 citations
,
July 2021 in “Dermatologic Therapy” 1 citations
,
November 2019 in “Dermatologic Therapy” January 2021 in “Dermatologic Therapy” November 2020 in “Dermatologic Therapy” May 2020 in “Dermatologic Therapy” March 2020 in “Dermatologic Therapy” January 2020 in “Dermatologic Therapy” June 2022 in “Zenodo (CERN European Organization for Nuclear Research)” The hydrogel with neem and tridax extracts effectively treats seborrheic dermatitis.
2 citations
,
July 2015 in “Case Reports in Dermatology” DDS treatment for LABD can cause severe side effects like anemia and hair loss, requiring careful monitoring.
June 2010 in “Melanoma research” LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.